Kaspersen SJ1, Han J2, Nørsett KG3, Rydså L4, Kjøbli E5, Bugge S6, Bjørkøy G7, Sundby E8, Hoff BH9.
Eur J Pharm Sci. 2014 Aug 1;59:69-82. doi: 10.1016/j.ejps.2014.04.011. Epub 2014 Apr 24.The epidermal growth factor receptor is an important target in molecular cancer therapy. Herein, the enzymatic inhibition potential of a series of chiral and non chiral pyrrolopyrimidine based derivatives have been investigated and optimised. Overall, seven new compounds were identified having enzymatic IC50 values comparable to or better than the commercial drug Erlotinib. High activity was also confirmed towards the epidermal growth factor receptor L858R and L861Q mutants. Read More